60 Leveroni Court
Novato, CA 94949
United States
415 483 8800
https://www.ultragenyx.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 1,276
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Dr. Emil D. Kakkis M.D., Ph.D. | Founder, President, CEO & Director | 1.46M | 1.27M | 1960 |
Mr. Howard Horn | Executive VP of Corporate Strategy & CFO | 184.81k | N/A | 1978 |
Ms. Karah Herdman Parschauer J.D. | Chief Legal Officer & Executive VP of Corporate Affairs | 846.74k | N/A | 1978 |
Mr. John Richard Pinion II | Chief Quality Operations Officer & Executive VP of Translational Sciences | 860.05k | N/A | 1966 |
Mr. Erik Harris | Executive VP & Chief Commercial Officer | 878.77k | N/A | 1971 |
Mr. Theodore A. Huizenga | Senior VP, Corporate Controller & Principal Accounting Officer | N/A | N/A | 1971 |
Mr. Ernie W. Meyer | Chief Human Resources Officer & Executive VP | N/A | N/A | 1965 |
Mr. Thomas R. Kassberg | Chief Business Officer & Executive VP | 714.84k | N/A | 1960 |
Mr. Vimal Srivastava | Senior Vice President of Business Development & Alliance Management | N/A | N/A | 1965 |
Mr. Dennis Karl Huang | Chief Technical Operations Officer and EVP of Gene Therapy Research & Development | 331.33k | N/A | 1965 |
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.
Ultragenyx Pharmaceutical Inc.’s ISS governance QualityScore as of 1 May 2024 is 4. The pillar scores are Audit: 2; Board: 2; Shareholder rights: 7; Compensation: 5.